Bicycle Therapeutics Plc
(NASDAQ : BCYC)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
MRNAModerna, Inc. 4.28%149.120.0%$4261.39m
NVAXNovavax, Inc. 2.00%127.9992.9%$676.86m
BIIBBiogen, Inc. -1.36%243.561.7%$663.10m
BNTXBioNTech SE -0.55%120.420.0%$647.20m
AMGNAmgen, Inc. 0.46%227.611.3%$599.44m
GILDGilead Sciences, Inc. -0.87%60.601.0%$513.73m
VRTXVertex Pharmaceuticals, Inc. -0.55%225.461.9%$489.14m
REGNRegeneron Pharmaceuticals, Inc. -0.79%501.142.7%$473.52m
ILMNIllumina, Inc. 0.91%343.943.5%$416.97m
APVOAptevo Therapeutics, Inc. -3.86%45.9218.3%$243.08m
EXASEXACT Sciences Corp. 4.49%130.0019.6%$186.30m
SGENSeagen Inc. 1.60%179.885.8%$177.78m
ALXNAlexion Pharmaceuticals, Inc. -2.08%120.202.0%$142.82m
SRNESorrento Therapeutics, Inc. 2.26%7.951.4%$134.92m
SRPTSarepta Therapeutics, Inc. 2.23%153.3113.8%$131.29m

Company Profile

Bicycle Therapeutics Plc is a holding company, which engages in the development of biopharmaceuticals. It focuses on developing a novel class of medicines, which the company refers to as bicycles, for diseases that are underserved by existing therapeutics. The firm utilizes its novel and proprietary phage display screening platform to identify bicycles. Its portfolio includes internal product candidates that are directed to oncology applications. The company was founded by Gregory Winter, John Tite, and Christian Heinis in 2009 and is headquartered in Cambridge, the United Kingdom.